SHANGHAI (Reuters) - A vaccine scandal in China, which has prompted angry reactions from leaders and citizens fed up with safety scares in the country, is sending ripples across the local drug market and threatening Chinese ambitions to play a larger global role.
Shares in Chinese vaccine makers and biotech firms fell across the board on Monday after Premier Li Keqiang slammed Changsheng Biotechnology Co for having crossed a moral red line and called for swift action.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!